Jun Yoon
Director of Finance/CFO at STRUCTURE THERAPEUTICS INC.
Net worth: 34 M $ as of 29/04/2024
Profile
Jun Yoon is currently the Chief Operating Officer & Director at Shanghai ShouTi Biotechnology Co. Ltd.
and the Chief Financial Officer at Structure Therapeutics, Inc. He previously worked as the Senior Director-Licensing & Business Development at VIA Pharmaceuticals, Inc. from 2004 to 2010, the Head-Business Development at Syrrx, Inc. from 2000 to 2002, and the Vice President-Corporate Development at Cellerant Therapeutics, Inc. from 2010 to 2016.
Mr. Yoon obtained his undergraduate degree from the University of California.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 18/04/2024 | 2,620,050 ( 1.87% ) | 34 M $ | 29/04/2024 |
Jun Yoon active positions
| Companies | Position | Start |
|---|---|---|
| STRUCTURE THERAPEUTICS INC. | Director of Finance/CFO | 30/04/2022 |
Shanghai ShouTi Biotechnology Co., Ltd.
 Shanghai ShouTi Biotechnology Co., Ltd. BiotechnologyHealth Technology Part of Structure Therapeutics, Inc., Shanghai ShouTi Biotechnology Co., Ltd. develops biotechnologies. The company is based in Shanghai, China. The CEO of the Chinese company is Xi Chen Lin. | Chief Operating Officer | - |
Former positions of Jun Yoon
| Companies | Position | End |
|---|---|---|
Cellerant Therapeutics, Inc.
 Cellerant Therapeutics, Inc. Medical SpecialtiesHealth Technology Cellerant Therapeutics, Inc. develops stem cell-based cellular and antibody therapeutics for blood disorders and cancer. The firm focuses on curative therapies for seriously ill patients and is developing a cell-based medicine as a treatment for chemotherapy and radiation-induced neutropenia as well as for Acute Radiation Syndrome. The company was founded by Irving L. Weissman in 2003 and is headquartered in San Carlos, CA. | Corporate Officer/Principal | 31/12/2015 |
| VIA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 28/02/2010 |
Syrrx, Inc.
 Syrrx, Inc. Pharmaceuticals: MajorHealth Technology Syrrx, Inc. used to develops drugs. Its focus was on creating novel therapies for cancer, metabolic diseases and inflammation. The company was the technology leader in the field of structural proteomics, the process of generating protein structures from genetic information. It was headquartered in San Diego, CA | Corporate Officer/Principal | 30/09/2002 |
Training of Jun Yoon
| University of California | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| STRUCTURE THERAPEUTICS INC. | Commercial Services |
| VIA PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Cellerant Therapeutics, Inc.
Cellerant Therapeutics, Inc. Medical SpecialtiesHealth Technology Cellerant Therapeutics, Inc. develops stem cell-based cellular and antibody therapeutics for blood disorders and cancer. The firm focuses on curative therapies for seriously ill patients and is developing a cell-based medicine as a treatment for chemotherapy and radiation-induced neutropenia as well as for Acute Radiation Syndrome. The company was founded by Irving L. Weissman in 2003 and is headquartered in San Carlos, CA. | Health Technology |
Syrrx, Inc.
Syrrx, Inc. Pharmaceuticals: MajorHealth Technology Syrrx, Inc. used to develops drugs. Its focus was on creating novel therapies for cancer, metabolic diseases and inflammation. The company was the technology leader in the field of structural proteomics, the process of generating protein structures from genetic information. It was headquartered in San Diego, CA | Health Technology |
Shanghai ShouTi Biotechnology Co., Ltd.
Shanghai ShouTi Biotechnology Co., Ltd. BiotechnologyHealth Technology Part of Structure Therapeutics, Inc., Shanghai ShouTi Biotechnology Co., Ltd. develops biotechnologies. The company is based in Shanghai, China. The CEO of the Chinese company is Xi Chen Lin. | Health Technology |
- Stock Market
- Insiders
- Jun Yoon
